Sage Therapeutics competitors, on the record

Who Sage Therapeutics names

In its own words

1. Brii Biosciences, Lipocine, Inc.

   Word for word“ZURZUVAE may also face competition from drugs currently in development, if successfully developed and approved in the future for the treatment of PPD, including potentially LPCN 1154, an oral formulation of the neuroactive steroid brexanolone under development by Lipocine, Inc. under the streamlined 505(b)(2) regulatory pathway, which allows for potential approval of an abbreviated NDA by the FDA, and BRII-296, an intramuscular formulation of brexanolone being developed by Brii Biosciences.” 10-K for 2024

2. Cerevel Therapeutics, Inc.

   Word for word“Other GABA A competitors include darigabat, which is being developed by Cerevel Therapeutics, Inc. (acquired by AbbVie Inc.) for the treatment of epilepsy and panic disorder.” 10-K for 2024

3. Marinus Pharmaceuticals, Inc.

   Word for word“In the field of neuroactive steroids focused specifically on modulation of GABA A receptors, we also face competition from a number of companies, including Marinus Pharmaceuticals, Inc. (acquired by Immedica Pharma AB), which received FDA approval of ganaxolone, a known GABA A positive allosteric modulator neuroactive steroid, to treat seizures associated with CDKL5 deficiency disorder, a rare, genetic epilepsy.” 10-K for 2024

Read from Sage Therapeutics’s annual reports (10-K for 2024, 10-K for 2023, 10-K for 2022) and the financial data it files with the SEC, as of 2025-02-11. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.